Metagenomi Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2023 | 50.3% | 50.3% | -18.7% |
| FY2024 | -33.2% | -33.2% | -24.0% |
| FY2025 | -55.4% | -55.4% | -39.7% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2023 | 50.3% | 50.3% | -18.7% |
| FY2024 | -33.2% | -33.2% | -24.0% |
| FY2025 | -55.4% | -55.4% | -39.7% |